Status:
ACTIVE_NOT_RECRUITING
BeGrow Study to Treat Pulmonary Artery (PA) Stenosis in Newborns and Infants
Lead Sponsor:
Bentley InnoMed GmbH
Conditions:
Pulmonary Artery Stenosis
Eligibility:
All Genders
Up to 24 years
Phase:
NA
Brief Summary
Objective of the study is to assess safety and performance of the BeGrow Stent System for newborns and infants in pulmonary artery stenosis.
Detailed Description
The Bentley InnoMed "BeGrow Stent System for Newborns and Infants" is a stent delivery system indicated for intraluminal placement in the pulmonary arteries of newborns and infants for the treatment o...
Eligibility Criteria
Inclusion
- Single lesion(s) which can be treated with a 6 mm BeGrow stent (only one stent per lesion allowed).
- Pulmonary artery stenosis - patient must at least have one of the following diseases:
- Haemodynamically relevant proximal or distal branch pulmonary artery stenosis with a reduction of the vessel diameter when the vessel/patient is large enough to accommodate a stent,
- Haemodynamically relevant stenosis of the main pulmonary artery segment that results in elevation of the Right Ventricle (RV) pressure, provided that the stent definitely will not compromise a functioning pulmonary valve and will not impinge on the pulmonary artery bifurcation,
- Any degree of stenosis in patients with single ventricle circulation
- Critically ill postoperative cardiac patients when it has been determined that branch pulmonary artery stenosis is resulting in a definite haemodynamic compromise in a patient/vessel of any size, particularly if balloon dilatation is unsuccessful
- Signed written informed consent (by parents/legal guardians)
- Lesion can be accessed with a guide wire or balloon catheter
- Age ≤ 24 months and weight ≥ 2 kg
- Adequate stent length available
Exclusion
- The following lesions are excluded from treatment with BeGrow stent:
- Shunt stenosis
- Valvular and subvalvular pulmonary stenosis
- Patients with known hypersensitivity to the stent material (L605 cobalt-chromium).
- Patients with clinical or biological signs of infection.
- Patients with active endocarditis.
- Patients with known allergy to acetylsalicylic acid, other antiplatelet agents or heparin.
- Presence of other previously implanted stents in the same lesion or in close proximity to stent (direct stent-stent contact).
- Patients with known coagulation disorder.
- Patients where direct stent-stent contact or overlapping cannot be avoided.
- Patients where contact to the vessel wall over the entire stent length cannot be ensured after dilatation (especially in short and thick lesions).
- Patients where the BeGrow stent could protrude freely into adjacent vessels after expansion/dilatation, including the pulmonary arterial bifurcation.
- Implantation of the BeGrow stent in the pulmonary arterial bifurcation.
Key Trial Info
Start Date :
March 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 31 2027
Estimated Enrollment :
18 Patients enrolled
Trial Details
Trial ID
NCT03287024
Start Date
March 1 2018
End Date
May 31 2027
Last Update
October 28 2024
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Medizinische Universität Wien, AKH Wien, Abteilung für Pädiatrische Kardiologie
Vienna, Austria, 1090
2
University Children's Hospital, Center for Pediatrics - Department of Cardiology
Belgrade, Serbia, 11000
3
Universitäts-Kinderspital Zürich
Zurich, Switzerland, 8032